Metraipolis › archive › dc_fe45aab37ab5
Unlocking new horizons in oncology: ivonescimab's dual-target approach to anti-VEGF/PD-1(L1) therapy — Europe PMC PMID:41333457
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41333457
- DOI
- 10.3389/fimmu.2025.1599181
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T12:12:28.276Z
- SHA-256 of the archived text
fb654469ca87dcaf8e554251734ee25e67fccb396840d26844cf09df3680e138- Stable URL of this page
https://metraipolis.com/documento/dc_fe45aab37ab5
How to cite
Unlocking new horizons in oncology: ivonescimab's dual-target approach to anti-VEGF/PD-1(L1) therapy — Europe PMC PMID:41333457 — Europe PMC (en), https://europepmc.org/article/MED/41333457 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fe45aab37ab5 (Metraipolis archive dc_fe45aab37ab5, sha256 fb654469ca87dcaf8e554251734ee25e67fccb396840d26844cf09df3680e138)
BibTeX
@misc{dcfe45aab37ab5,
title = {Unlocking new horizons in oncology: ivonescimab's dual-target approach to anti-VEGF/PD-1(L1) therapy — Europe PMC PMID:41333457},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41333457},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fe45aab37ab5; sha256 fb654469ca87dcaf8e554251734ee25e67fccb396840d26844cf09df3680e138},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41333457. Agents can read the archived copy with the MCP tool read_document.